The Division of Hematologic Malignancies is led by Marcel R.M. van den Brink (left), an expert in bone marrow transplants to treat people with blood cancer. MSK is a leader in bone marrow transplant research.
The Division of Hematologic Malignancies within MSK’s Department of Medicine is dedicated to treating patients with a variety of blood cancers, as well as some benign hematologic diseases. Our physicians and scientists are central players in advancing translational and clinical research and establishing the standard of care for patients with hematologic cancers.
Our Department is organized into four divisions:
The Division of Hematologic Malignancies is led by Marcel R.M. van den Brink, MD, PhD, and includes the:
- Adult Bone Marrow Transplant Service
- Cellular Therapy Service
- Hematology Service
- Leukemia Service
- Lymphoma Service
- Myeloma Service
Marcel R.M. van den Brink, MD, PhD, is Head of the Division of Hematologic Malignancies. Dr. van den Brink is a leading medical oncologist and physician-scientist who is internationally recognized for his expertise in bone marrow transplantation for blood cancers and his research contributions to cancer therapeutics. In recent years, Dr. van den Brink has been at the forefront of investigating the importance of the gut microbiome in cancer therapies such as hematopoietic stem cell transplantation. Dr. van den Brink broadly studies strategies to improve allogeneic blood stem cell transplantation and cellular therapy, as well as techniques to help the body rebuild the immune system after bone marrow transplantation in the Marcel van den Brink Lab and in clinical trials conducted at MSK.
